A Registry-study of ELZONRIS in Participants With BPDCN
About this study
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
- Condition
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Tested
- Tagraxofusp
- Sponsor
- Stemline Therapeutics, Inc.
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Study condition: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56).
- Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment.
Exclusion 4
- Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported.
- Participating in an interventional clinical trial at the time of ICF signature.
- Known allergic reactions to components of tagraxofusp.
- Note: Other protocol-specified criteria apply.
Where
41 sites, 41 recruiting
Medical University Innsbruck
Innsbruck, Austria
Ordensklinikum Linz Krankenhaus der Elisabethinen Linz
Linz, Austria
Salzburg Cancer Research Institute (SCRI)
Salzburg, Austria
Medizinische Universitat Wien, Department for Internal Medicine I, Division of Hematology and Haemostaseology
Vienna, Austria
Universitätsklinikum Augsburg
Augsburg, Germany
Hospital Bielefeld
Bielefeld, Germany
and 35 more sites on ClinicalTrials.gov
Contact
-
Stemline Trials
1-877-332-7967 clinicaltrials@menarinistemline.com
Potential match only. Final eligibility is determined by the study team.